pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 9·1 min read
save

Ending federally funded animal testing could stall xenotransplantation breakthroughs

Jun 9, 2026·read at STAT ↗RegulatoryNegative

Transplant surgeon Joshua Mezrich argues that recent moves to end federally funded animal testing could impede the development of xenotransplantation, a field that aims to use pig organs for human patients.

Health secretary Robert F. Kennedy Jr. has called for a complete ban on federal animal experiments, claiming that animal models poorly predict human health outcomes.

The Centers for Disease Control and Prevention is already phasing out primate studies and relocating animals to sanctuaries, while the National Institutes of Health has stopped issuing funding opportunities that focus solely on animal models and has closed one of its eight National Primate Research Centers.

Mezrich warns that these policy shifts risk delaying clinical trials that could transform lives, as the scientific community still relies on animal data to move pig organ transplants toward human use.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough”

read at STAT ↗
1,548 words · retrieved Jun 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
National Institutes of Health2UNITED THERAPEUTICS Corp
topics
Nephrology6CRISPR/Cas94Cardiology4Gene Therapy (AAV)2Monoclonal Antibody2Vaccines

related stories

  • 6h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech
  • 2d agoBeyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical modelsBioSpace
  • Jul 9STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugsSTAT